

CORRECTION

Open Access



Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Letong Cai^{1†} , Yuchen Li^{1†} , Jiaxiong Tan^{1†} , Ling Xu^{1,2*} and Yangqiu Li^{1,2*}

Correction to:

Cai et al. *Journal of Hematology & Oncology* (2023)
16:101
<https://doi.org/10.1186/s13045-023-01499-1>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article [1] contained an error mistakenly introduced by the production team whereby co-first authorship for the first three co-authors was omitted. This has since been restored accordingly.

Published online: 29 September 2023

Reference

1. Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. *J Hematol Oncol.* 2023;16:101. <https://doi.org/10.1186/s13045-023-01499-1>.

[†]Letong Cai, Yuchen Li and Jiaxiong Tan contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s13045-023-01499-1>.

*Correspondence:

Ling Xu

lingxu114@163.com

Yangqiu Li

yangqiuli@hotmail.com

¹ Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China

² Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou 510632, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.